Announcing our newest cancer test. Screen cancer early with Onco-D-clare. Learn more
In the evolving landscape of cancer care, immunotherapy is changing cancer treatment forever. We're proud to offer Clavic-Q-RE, a groundbreaking cancer immunotherapy treatment that harnesses the innate power of a patient's own immune system to fight cancer. This autologous approach to personalized cancer care represents the next generation of precision medicine, offering hope to patients seeking alternatives beyond traditional chemotherapy and radiation.
Clavic-Q-RE stands as a pioneering immunotherapy treatment for cancer that is a minimally manipulated cellular therapy also known as Autologous Adoptive Cellular Therapy. This innovative therapy is a significant advancement in personalized cancer care, offering patients a targeted approach that works with their body's natural defense mechanisms.
Clavic-Q-RE contains a comprehensive arsenal of both innate and adaptive immune cells, creating a multi-faceted approach to cancer treatment. The therapy includes:
This combination ensures both immediate and sustained immune response against cancer cells, making it one of the most comprehensive cancer immunotherapy treatments available today.
The mechanism of action behind Clavic-Q-RE demonstrates why immunotherapy in cancer treatment has become such a promising field. The therapy works through multiple complementary pathways to identify, target, and eliminate cancer cells throughout the body.
Clavic-Q-RE is administered as three carefully timed doses, each containing both innate and adaptive immune cells. This staged approach allows for:
The therapy timeline spans four weeks, with doses administered every two weeks, allowing the immune system to build upon each treatment while maintaining therapeutic momentum.
Understanding patient eligibility is crucial for the success of any immunotherapy treatment for cancer. Clavic-Q-RE has specific indications and considerations that determine its appropriateness for individual patients.
Clavic-Q-RE demonstrates effectiveness against a broad spectrum of malignancies, including:
The therapy's versatility stems from its ability to target patient-specific cancer antigens, making it adaptable to many different cancer types. The personalized nature of the treatment means it can be tailored to target the unique molecular signature of each patient's cancer.
Currently, Central Nervous System (CNS) cancers are not candidates for Clavic-Q-RE therapy due to the blood-brain barrier. This physiological barrier prevents the therapeutic immune cells from effectively reaching brain tumors, limiting the therapy's effectiveness in treating primary brain cancers and brain metastases.
Clavic-Q-RE is appropriate for patients who meet specific staging criteria:
This therapy often serves as an excellent option for patients seeking alternatives after conventional treatments have reached their limits, provided their overall health status supports immune-based therapy.
Understanding the practical aspects of Clavic-Q-RE therapy helps patients prepare for treatment and know what to expect throughout the process.
As an autologous therapy using the patient's own immune cells, Clavic-Q-RE maintains an excellent safety profile. The use of the patient's own cells eliminates the risk of immune rejection and significantly reduces the potential for severe adverse reactions.
The therapy has been extensively studied and refined to minimize risks while maximizing therapeutic benefit. Since the immune cells are derived from a patient's own blood, there is no risk of infectious disease transmission or compatibility issues that might occur with donor-derived therapies.
Before beginning Clavic-Q-RE therapy, patients must complete testing to ensure safety and optimize treatment outcomes:
These pre-therapy requirements ensure that patients are optimal candidates for immunotherapy and help predict treatment outcomes.
While Clavic-Q-RE maintains an excellent safety profile, patients may experience some reactions as their immune system becomes activated:
Rare considerations:
Most reactions are generally mild and temporary, often indicating that the immune system is responding to the therapy. Patients are closely monitored throughout treatment by their practitioner.
The Clavic-Q-RE treatment protocol follows a carefully designed timeline:
Phase 1: Preparation
Phase 2: Treatment
Phase 3: Monitoring
The therapy preparation takes approximately 21 days from blood collection to receipt of the first dose, during which time immune cells which have been activated by the patient’s autologous antigens are selected and isolated.
Two specific tests are mandatory components of the Clavic-Q-RE package:
Oncotrace: This advanced test monitors CTC count, phenotype markers, and stemness markers, providing crucial information about cancer activity and treatment response. The test helps track therapeutic effectiveness and detect early signs of disease progression or remission.
Immune-Frame: This comprehensive immune system analysis evaluates the patient's immune status, including immune cell populations, functionality, and overall immune competence. This testing ensures the patient's immune system can support and benefit from immunotherapy.
These tests are performed both before treatment initiation and after treatment completion to assess therapeutic response and guide ongoing care.
Several factors may preclude patients from receiving Clavic-Q-RE therapy:
These contraindications exist to ensure patient safety and therapeutic effectiveness. Patients with these conditions may be considered for immunotherapy cancer treatment once the contraindicated condition is resolved or managed.
Patients should consult with their RGCC Practitioner about other potential contraindications.
The effectiveness of cancer immunotherapy treatments like Clavic-Q-RE continues to be documented through clinical research and patient outcomes. Recent scientific publications demonstrate promising results for this innovative therapy approach.
A peer-reviewed study published in Cancer Letters provides compelling evidence of Clavic-Q-RE's therapeutic potential. The research demonstrates improvement in patient outcomes, including enhanced immune response, tumor reduction, and improved quality of life measures.
The personalized nature of this immunotherapy contributes to its effectiveness, as each treatment is specifically designed to target the individual patient's cancer characteristics and immune profile.
In the rapidly evolving field where immunotherapy is changing cancer treatment forever, Clavic-Q-RE offers clear advantages that set it apart from other treatment options:
Personalized Approach: Every dose is created specifically from your immune cells and targeted to your cancer antigens, ensuring maximum compatibility and effectiveness.
Comprehensive Immune Response: Unlike single-target therapies, Clavic-Q-RE activates multiple immune pathways, creating a robust, multi-faceted attack against cancer cells.
Excellent Safety Profile: As an autologous therapy, the risk of severe adverse reactions is minimized while therapeutic benefits are maximized.
Proven Science: Backed by peer-reviewed research and developed by RGCC's team of internationally recognized scientists and researchers.
Global Accessibility: Available through RGCC's international network of trained practitioners who specialize in personalized cancer care.
Complementary Care: Can be integrated into comprehensive treatment plans, working alongside other therapies when appropriate.
Immunotherapy represents the culmination of decades of research in cancer immunology and personalized medicine, offering hope to patients who need advanced treatment options.
Explore how a new cancer treatment immunotherapy like Clavic-Q-RE could benefit your specific situation.
A personalized treatment journey is a source of confidence, knowing you're working with pioneers in cancer immunotherapy who are committed to advancing patient care through scientific innovation.
Contact RGCC today to discover how Clavic-Q-RE can become part of your fight against cancer.
Explore our curated collection of videos, providing an in-depth look at our innovative solutions and groundbreaking research.
In this insightful interview from the 2023 RGCC Gathering, Dr. Clayton Bell shares his journey of integrating RGCC technologies into his practice in the U.S.
With a background in Functional, Environmental, and Integrative Medicine, Dr. Bell reveals how he uses RGCC’s cutting-edge cancer diagnostics and therapies to support his patients’ healing. Watch the full video to learn more.
Helena Pöhlmann who specializes in holistic medicine shares how she utilizes RGCC products in her clinic to best support her patients. Watch the video to learn about her experience at the 2023 RGCC Gathering in Switzerland.
Cancer survivor and RGCC Practitioner, Jenny Hrbaceck, discusses RGCC testing and the impact it has made on her life.
Watch an interview with Dr. Bita Badakhshan, a seasoned practitioner in primary family medicine with over 12 years of experience in integrative oncology and functional medicine.
In this video, Dr. Bita shares her experience with RGCC’s transformative liquid biopsy testing. She highlights the unparalleled precision and detail offered by RGCC's advanced methodologies over other laboratories.
Dr. Bita emphasizes the unmatched sensitivity of RGCC's testing, which delves deep into analyzing stem cells, cancer cells, and a comprehensive array of markers crucial for personalized cancer care.
Since 2012, Dr. Beta has trusted RGCC for blood testing on patients, particularly focusing on circulating tumor cell analysis and using RGCC’s Oncocount and Oncotrace tests along with the Onconomics Plus assessments.
Through RGCC's innovative tests and therapies, Dr. Bita has been able to make informed decisions sparing many patients from unnecessary chemotherapy and radiation post-tumor removal surgeries.
Join host Sam Tejada for an essential conversation about cancer innovation and breakthroughs on this episode of A Healthy Point of View, including a close look at advances in early cancer detection - as early as stage ZERO.
Tejada sits down with two leading medical experts: Dr. Christopher Davis, an interventional cardiologist and CMO of Liquivida, and Dr. Ioannis Papasotiriou, MD, PhD, SCym, the founder of RGCC.
Together, they tackle one of medicine's most complex challenges, sharing cutting-edge insights and breakthrough approaches that could transform how we understand and address cancer care.
Explore our curated collection of videos, providing an in-depth look at our innovative solutions and groundbreaking research.
In this insightful interview from the 2023 RGCC Gathering, Dr. Clayton Bell shares his journey of integrating RGCC technologies into his practice in the U.S.
With a background in Functional, Environmental, and Integrative Medicine, Dr. Bell reveals how he uses RGCC’s cutting-edge cancer diagnostics and therapies to support his patients’ healing. Watch the full video to learn more.
Helena Pöhlmann who specializes in holistic medicine shares how she utilizes RGCC products in her clinic to best support her patients. Watch the video to learn about her experience at the 2023 RGCC Gathering in Switzerland.
Cancer survivor and RGCC Practitioner, Jenny Hrbaceck, discusses RGCC testing and the impact it has made on her life.
Watch an interview with Dr. Bita Badakhshan, a seasoned practitioner in primary family medicine with over 12 years of experience in integrative oncology and functional medicine.
In this video, Dr. Bita shares her experience with RGCC’s transformative liquid biopsy testing. She highlights the unparalleled precision and detail offered by RGCC's advanced methodologies over other laboratories.
Dr. Bita emphasizes the unmatched sensitivity of RGCC's testing, which delves deep into analyzing stem cells, cancer cells, and a comprehensive array of markers crucial for personalized cancer care.
Since 2012, Dr. Beta has trusted RGCC for blood testing on patients, particularly focusing on circulating tumor cell analysis and using RGCC’s OncoCount and OncoTrace tests along with the Onconomics Plus assessments.
Through RGCC's innovative tests and therapies, Dr. Bita has been able to make informed decisions sparing many patients from unnecessary chemotherapy and radiation post-tumor removal surgeries.
Read more about our therapies on our website: https://rgcc-international.com/rgcc-therapies/
RGCC was launched in 2004 by genetics pioneer Dr. Ioannis Papasotiriou who believes that the key to effectively treating cancer lies in personalized medicine using the information in a patient’s genes.
Individualized treatment for cancer is the focus behind RGCC’s testing protocols and advanced therapy options. Our slate of tests analyzes the state of a person’s cancer by looking at the cellular and genetic makeup of each patient. Our test results give you information that acts as a blueprint for what treatment protocols are likely to show the most efficacy for your specific biology.
Learn more about RGCC at
https://rgcc-international.com/
Follow us on social media to find out the latest news and updates from our experts.
Facebook: https://www.facebook.com/profile.php?id=61554630098937
Instagram: https://www.instagram.com/rgcc_north_america/
LinkedIn: https://www.linkedin.com/company/r-g-c-c-international-gmbh/
Join host Sam Tejada for an essential conversation about cancer innovation and breakthroughs on this episode of A Healthy Point of View, including a close look at advances in early cancer detection - as early as stage ZERO.
Tejada sits down with two leading medical experts: Dr. Christopher Davis, an interventional cardiologist and CMO of Liquivida, and Dr. Ioannis Papasotiriou, MD, PhD, SCym, the founder of RGCC.
Together, they tackle one of medicine's most complex challenges, sharing cutting-edge insights and breakthrough approaches that could transform how we understand and address cancer care.
